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Summary  Catheter-based  renal  denervation  is  a  new  method  for  disrupting  renal  sympa-
thetic nerves  in  the  adventitia  of  renal  arteries.  A  randomized  clinical  trial  showed  a  decrease
Abbreviations: ABP, ambulatory blood pressure; ACC, American College of Cardiology; BP, blood
ressure; DBP, diastolic blood pressure; GFR, glomerular ﬁltration rate; HBP, home blood pressure; SBP, systolic blood pressure.
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in  blood  pressure  (BP)  in  resistant  hypertensive  patients.  To  guide  clinicians  and  interventional
practitioners  in  the  use  of  this  new  approach,  the  French  Societies  of  Arterial  Hypertension,
Cardiology  and  Radiology  decided  to  combine  their  expertise  and  propose  a  consensus  document
assessing the  beneﬁt/risk  ratio  of  this  technique  in  arterial  hypertension.  In  2012,  this  expert
consensus proposed  limiting  renal  denervation  to  patients  with  essential  hypertension  uncon-
trolled by  four  or  more  antihypertensive  therapies  and  with:  treatment  that  includes  at  least  a
diuretic; past  or  present  exposure  to  spironolactone  (at  a  dose  ≥  25  mg/d);  and  ofﬁce  BP  greater
or equal  to  160  mmHg  and/or  100  mmHg  for  systolic  and  diastolic  BP,  respectively,  conﬁrmed
by daytime  ambulatory  or  home  BP  measurement,  with  systolic  BP  greater  than  135  mmHg  and
diastolic  BP  greater  than  85  mmHg.  Finally,  renal  artery  anatomy  and  kidney  function  should
allow proper  intervention  (i.e.  two  functional  kidneys,  absence  of  previous  renal  angioplasty).
Renal denervation  is  a  complex  interventional  procedure  requiring  appropriate  training  and
associated  with  arterial  complications.  Antihypertensive  treatment  should  not  be  interrupted
immediately  after  renal  denervation  as  the  BP-lowering  effect  is  delayed  and  reaches  maximum
effect after  3  months.  Monitoring  of  BP,  renal  function  and  renal  artery  anatomy  is  required
12 months  and  36  months  after  the  procedure.  The  expert  consensus  requires  the  inclusion  of
patients experiencing  this  procedure  in  an  observational  study.
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Résumé  La  dénervation  rénale  par  voie  endovasculaire  est  une  méthode  nouvelle  qui  permet
la destruction  de  ﬁbres  nerveuses  sympathiques  qui  cheminent  dans  l’adventice  des  artères
rénales. Une  étude  clinique  randomisée  a  montré  une  baisse  de  la  pression  artérielle  chez
des hypertendus  résistants  aux  médicaments  antihypertenseurs.  Plusieurs  sociétés  savantes
franc¸aises regroupant  des  spécialistes  de  l’hypertension  artérielle,  de  la  cardiologie  et  de
la radiologie  interventionnelle  ont  souhaité  fournir  des  repères  et  des  règles  de  bon  usage
aux médecins  cliniciens  et  interventionnels  concernant  cette  méthode.  En  2012,  le  consensus
d’expert  limite  l’indication  de  la  technique  de  dénervation  rénale  aux  patients  qui  ont  une  HTA
essentielle  non  contrôlée  sous  quadrithérapie  ou  plus,  avec  un  traitement  comportant  au  moins
un diurétique,  la  spironolactone  à  la  dose  de  25  mg  ayant  été  inefﬁcace,  avec  au  moins  une  PAS
supérieure  à  160  mmHg  et/ou  une  PAD  supérieure  à  100  mmHg  en  consultation  et  la  conﬁrma-
tion d’une  PAS  supérieure  à  135  mmHg  et  d’une  PAD  supérieure  à  85  mmHg  en  automesure  ou
par MAPA  (période  diurne),  avec  anatomie  des  artères  rénales  compatible  avec  l’intervention
(deux reins  fonctionnels,  absence  d’antécédents  d’angioplastie).  La  dénervation  rénale  est  une
intervention  complexe  pouvant  présenter  des  risques  de  complication  artérielle  et  une  forma-
tion est  nécessaire  pour  l’utilisation  du  matériel  spéciﬁque.  Le  traitement  antihypertenseur  ne
sera pas  interrompu  dans  les  suites  immédiates  du  geste  de  dénervation  rénale  car  l’effet  sur
la baisse  de  la  pression  artérielle  est  retardé  et  atteint  son  effet  maximum  après  trois  mois.
La surveillance  de  la  pression  artérielle,  de  la  fonction  rénale  et  de  l’anatomie  des  artères
rénales est  nécessaire  après  12  mois  et  36  mois.  Le  consensus  d’expert  impose  l’inclusion  dans  un
registre spéciﬁque  de  tous  les  patients  ayant  bénéﬁcié  en  France  de  la  technique  de  dénervation
rénale.
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Catheter-based  radiofrequency  renal-nerve  ablation  via  an
endovascular  approach  is  a  new  therapeutic  option,  which,
according  to  a  randomized  clinical  study,  reduces  blood
pressure  (BP)  in  patients  with  resistant  hypertension.  Since
2011,  a  speciﬁc  system  (the  Symplicity® Catheter  SystemTM;
Medtronic  [Ardian]  Inc.,  Minneapolis,  MN,  USA)  has  been
commercially  available  in  France.  This  system  achieves  renal
denervation  through  the  focal  delivery  of  four  to  six  low
power  radiofrequency  energy  ablations  (5—8  W)  along  the
length  of  both  renal  arteries.  The  thermal  effect  generated
by  heat  dissipation  disrupts  the  sympathetic  nerves  located
in  the  adventitia  of  the  renal  artery.
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tTo date,  the  indication  for  this  system  is  not  explic-
tly  described  in  current  recommendations  and  instructions
or  use.  Therefore,  the  French  Society  of  Arterial
ypertension,  the  French  Society  of  Cardiology  and
he  French  Society  of  Radiology  decided  to  provide
uidelines  for  interventional  and  clinical  physicians  on
ndications  for  and  procedural  and  follow-up  aspects  of
enal  denervation  for  the  treatment  of  arterial  hyperten-
ion.
The  present  document  represents  a  consensus  of  lead-
ng  experts  in  this  ﬁeld  and  will  be  amended  to  keep
n  line  with  improvements  in  devices  and  procedures,
nd  the  outcome  of  future  clinical  trials  with  this
echnique.
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esistant hypertension: diagnosis and
urrent patient management
rterial  hypertension  is  the  most  frequent  cardiovascu-
ar  risk  factor  and  chronic  disease  recorded  in  France,
ith  more  than  12  million  patients  (20%)  being  treated
ith  antihypertensive  drugs.  Despite  established  treat-
ent  strategies  to  address  this  issue,  control  of  treated
ypertension—deﬁned  by  an  ofﬁce  systolic  blood  pressure
SBP)  less  than  140  mmHg  and  diastolic  blood  pressure  (DBP)
ess  than  90  mmHg—is  still  only  achieved  in  50%  of  patients
nder  treatment  [1].
Hypertensive  patients  who  do  not  achieve  target  blood
ressure  values  are  described  as  patients  with  uncontrolled
rterial  hypertension.  In  such  circumstances,  appropriate
anagement  includes:  the  need  to  comply  with  lifestyle
easures,  such  as  reduction  of  salt  or  alcohol  intake,
eight  loss,  etc.;  assessment  of  adequate  patient  adher-
nce  to  prescribed  treatments;  and  rationalized  use  of
ntihypertensive  medications,  with  optimal  selection  of
harmacological  classes  with  additive  and/or  synergistic
ffects.  When  single-medication  treatment  has  been  proven
nefﬁcient,  combination  therapy  should  be  set  up,  including
 renin-angiotensin  system  blocker  (angiotensin  II  receptor
locker,  angiotensin  I  converting  enzyme  inhibitor  or  direct
enin  inhibitor),  a  calcium  channel  blocker  and  a  thiazide
iuretic.
Patients  in  whom  target  ofﬁce  BP  values  are  not  reached
espite  prescription  of  triple  therapy,  including  a  thiazide
iuretic  at  maximum  tolerated  dose,  are  deﬁned  as  having
esistant  hypertension,  according  to  the  current  guide-
ines  of  the  European  Society  of  Hypertension  [2].  The
iagnosis  of  resistant  hypertension  should  be  conﬁrmed
s  follows:  ambulatory  BP  (ABP)  monitoring  or  self  BP
easurement  at  home  (HBP)  to  conﬁrm  that  BP  is  perma-
ently  uncontrolled,  with  values  greater  than  135  and/or
5  mmHg  during  the  daytime;  and  a  complete  biological
nd  imaging  workup  to  exclude  secondary  hypertension  [2],
ncluding  chronic  kidney  disease  of  various  origins,  sleep
bstructive  apnoea,  primary  aldosteronism,  pheochromocy-
oma  or  signiﬁcant  renal  artery  stenosis  and  drug-induced
ypertension.
When  conﬁrmed,  resistant  hypertension  requires  spe-
iﬁc  patient  management  as  indicated  in  the  international
uidelines  and  listed  below  [2]:  antihypertensive  treatment
osage  increase  or  adaptation  (use  of  maximum  toler-
ted  dose  of  antihypertensive  agents,  selection  of  another
iuretic,  such  as  a  loop  diuretic,  in  chronic  kidney  disease
atients);  addition  of  a  mineralocorticoid  receptor  antag-
nist,  such  as  a  low  dose  of  spironolactone  (25—50  mg/d);
ddition  of  other  pharmacological  agents  (alpha-blockers,
eta-blockers,  centrally  acting  antihypertensive  agents,
irect  vasodilators);  use  of  ﬁxed  combinations  of  antihyper-
ensive  agents;  use  of  HBP  to  monitor  treatment  efﬁcacy;
nd  reinforcement  of  a  salt-restricted  diet.
The  prevalence  of  resistant  hypertension  varies  accord-
ng  to  population  characteristics.  It  was  seen  in  about  9%  of
reated  hypertensive  patients  among  a  general  population
f  patients  living  in  the  USA  between  2003  and  2008  in  the
HANES  study  [3].  In  the  USA,  a  recent  survey  indicated  that
mong  205,750  patients  with  incident  hypertension,  1.9%
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eveloped  resistant  hypertension  within  a median  1.5  years
f  initial  treatment  (or  0.7  cases  per  100  person-years  of
ollow-up)  [4].
Patients  with  resistant  hypertension  are  exposed  prema-
urely  to  target  organ  dysfunction  and  to  early  occurrence
f  cardiovascular,  cerebrovascular  and  renal  complications,
eading  to  increased  mortality.  The  cardiovascular  prognosis
n  hypertensive  patients  is  directly  related  to  on-treatment
P  levels,  which  warrants  proactive  management  of  BP
reatment  [5].
In  patients  with  resistant  hypertension,  BP  control  may  be
mproved  via  the  implementation  of  device-based  therapies
hat  target  the  sympathetic  or  parasympathetic  regulation
f  BP,  including  baroreﬂex  activation  therapy  and  catheter-
ased  renal  denervation  [6,7].
The  objective  of  the  present  expert  consensus,  based
n  a  literature  review  and  the  experts’  experience,  is  to
ropose  a  statement  about  the  use  of  renal  denervation  in
atients  with  resistant  hypertension.  This  document  should
elp  clinicians  to  optimize  indications,  provides  guidelines
bout  appropriate  technical  implementation,  and  outlines
atient  follow-up  requirements.
athophysiological mechanisms and
rerequisites for catheter-based renal
enervation in hypertension
ole of the autonomic nervous system in
ypertension pathophysiology
he  autonomic  nervous  system  contributes  to  hypertension
athophysiology  via  the  activation  of  the  sympathetic  sys-
em,  which  is  regulated  by  excitatory  and  inhibitory  reﬂexes
baro-,  chemo-  or  mechanoreﬂexes)  or  various  neurohor-
ones  [8].  The  role  of  the  renal  sympathetic  nervous  system
n  BP  regulation  is  complex  due  to  the  impact  of  the  cen-
ral  efferent  sympathetic  tone  on  the  kidneys  and  the  role
f  afferent  sympathetic  signals  from  the  kidneys  towards
he  central  autonomic  centres.  Thus,  the  renal  sympathetic
ystem,  which  contributes  to  BP  regulation,  is  considered
s  one  among  multiple  systems  involved  in  the  initiation,
rogression  and  persistence  of  hypertension.
ole of the renal sympathetic nervous system
fferent  renal  sympathetic  nerve  activity  and  BP
egulation
he  efferent  sympathetic  innervation  of  the  kidneys  directly
nﬂuences  the  regulation  of  the  vascular  system,  the  renal
ubules  and  the  juxtaglomerular  apparatus.  Stimulation  of
he  sympathetic  system  contributes  to  vascular  constric-
ion  via  two  mechanisms:  stimulation  of  the  beta-adrenergic
eceptors  of  the  juxtaglomerular  apparatus,  resulting  in
he  increase  of  renin  release  and  thus  increasing  plasma
nd  tissue  concentrations  of  the  vasoconstrictor  peptide,
ngiotensin  II;  and  stimulation  of  vascular  alpha-adrenergic
eceptors,  eliciting  direct  vascular  constriction.  Moreover,
ympathetic  nervous  system  activation  also  increases  tubu-
ar  sodium  reabsorption  either  directly  or  indirectly,  thus
ontributing  to  an  increase  in  overall  extracellular  ﬂuid
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volume.  Consequently,  reduction  of  efferent  renal  sympa-
thetic  tone  in  an  experimental  model  of  renal  denervation
has  been  associated  with  a  decrease  in  BP  [9].
Afferent  renal  sympathetic  nerve  activity  and  BP
regulation
Renal  sympathetic  afferent  nerves  contribute  to  the  reg-
ulation  of  the  central  sympathetic  nervous  system.  They
are  activated  by  various  stimuli  detected  by  mechano-  or
chemoreceptors  located  in  the  kidneys,  which  are  sensitive
to  kidney  stretch,  various  concentrations  of  metabolites  or
oxygen  levels  (i.e.  hypoxia  resulting  from  renal  ischaemia
[10]).  The  interruption  of  renal  sympathetic  signalling  by
surgical  or  chemical  intervention  decreases  both  total  sym-
pathetic  activity  and  BP  [11], and  prevents  the  increase
in  BP  induced  by  various  experimental  conditions,  such  as
nephrectomy.
In  the  early  1950s,  the  use  of  surgical  renal  denervation
in  patients  with  arterial  hypertension  resulted  in  decreases
in  BP,  morbidity  and  mortality,  peripheral  and  central  sym-
pathetic  activity  and  renin  release  without  any  modiﬁcation
of  glomerular  ﬁltration  rate  (GFR).  The  availability  of  effec-
tive  orally  active  antihypertensive  treatments  and  the  high
incidence,  severity  and  duration  of  surgery-related  adverse
events  (including  postoperative  death,  severe  orthostatic
hypotension,  sphincter  incontinence,  sexual  dysfunction
and  paradoxical  excessive  sweating)  explains  why  surgical
denervation  techniques  (splanchnectomy,  sympathectomy)
were  abandoned  in  the  1960s  [12—15].
Renal denervation by radiofrequency via the
endovascular approach
Catheter-based  renal  sympathetic  denervation  by  radiofre-
quency  is  a  new  method  that  can  disrupt  both  the  efferent
and  afferent  sympathetic  nervous  ﬁbres  that  follow  the
renal  artery  to  the  kidney  within  the  adventitia.  This,  in
turn,  reduces  renal  sympathetic  tone  and  subsequently  BP.
Clinical trials of catheter-based renal
denervation in the treatment of resistant
hypertension
The SYMPLICITY HTN-1 and HTN-2 trials
Two  clinical  trials  have  assessed  the  effects  of  renal  den-
ervation  using  radiofrequency  in  patients  with  resistant
hypertension  [16,17].  SYMPLICITY  HTN-1,  conducted  in  50
patients,  was  mainly  a  pilot  feasibility  and  safety  study  and
reported  BP  reductions  with  no  major  complications  [16].
SYMPLICITY  HTN-2  was  an  open-label  randomized  study  of
106  among  190  preselected  patients  with  resistant  hyper-
tension,  with  the  aim  of  assessing  the  efﬁcacy  of  renal
denervation  in  reducing  ofﬁce  BP  values  after  6  months  com-
pared  with  a  control  group  of  medically  treated  patients.
In  both  groups,  no  change  in  antihypertensive  medication
was  allowed  during  the  ﬁrst  6  months.  Inclusion  criteria  were
very  similar  in  both  trials.
The  deﬁnition  of  resistant  hypertension  in  these  two
trials  was  as  follows:  ofﬁce  SBP  (average  of  three
p
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easurements)  greater  than  160  mmHg  or  150  mmHg  in
iabetics;  treatment  with  at  least  three  antihypertensive
edications,  including  a  diuretic  (only  in  SYMPLICITY  HTN-
);  persistence  of  uncontrolled  hypertension  after  a  run-in
eriod  of  15  days;  appropriate  adherence  to  treatment  as
ssessed  during  screening;  absence  of  severe  renal  insufﬁ-
iency  (estimated  GFR  >  45  mL/min/1.73  m2).
Renal  arterial  anatomy  was  required  to  be  suitable  for
he  endovascular  denervation  technique,  according  to  the
ollowing  criteria:  main  renal  artery  on  each  side  at  least
0  mm  in  length  and  4  mm  in  diameter;  and  an  absence  of
enal  artery  stenosis  or  no  history  of  renal  revascularization
rocedure.  In  both  SYMPLICITY  trials,  the  renal  denerva-
ion  procedure  was  not  feasible  in  10—20%  of  preselected
atients  due  to  anatomical  reasons.
ffects of renal denervation on BP
he  primary  efﬁcacy  endpoint  was  the  change  in  ofﬁce  BP
ssessed  6  months  after  the  renal  denervation  procedure
n  both  the  SYMPLICITY  HTN-1  and  HTN-2  trials  [16—18].
n  86  patients  issued  from  a  group  of  153  patients  (i.e.
he  extended  cohort  of  SYMPLICITY  HTN-1),  the  mean
ecrease  in  ofﬁce  SBP/DBP  was  —25/—11  mmHg.  In  SYM-
LICITY  HTN-2,  the  mean  change  in  ofﬁce  SBP/DBP  was
32/—12  mmHg  in  49  patients  undergoing  renal  denerva-
ion  and  +1/0  mmHg  in  the  51  medically  treated  control
roup  (P  <  0.0001).  At  12  months  after  randomization,  the
ean  ofﬁce  SBP/DBP  decrease  was  —28/—10  mmHg  but  the
ean  SBP/DBP  increased  by  +4/+3  mmHg  compared  with
he  6-month  values  (American  College  of  Cardiology  [ACC]
012  meeting)  (Table  1).  In  the  35  patients  in  the  control
roup  who  crossed  over  6  months  after  randomization  and
ad  renal  denervation,  the  mean  decrease  in  ofﬁce  SBP/DBP
as  —28/—8  mmHg,  6  months  after  the  procedure  (ACC  2012
eeting).
The  percentage  of  patients  with  SBP  less  than  140  mmHg
fter  renal  denervation  was  39%;  this  indicates  that  61%  of
he  patients  remained  with  uncontrolled  BP  despite  renal
enervation.  In  the  35  patients  who  crossed  over,  the  per-
entage  of  patients  with  SBP  less  than  140  mmHg  after
 months  of  renal  denervation  was  much  smaller  (10—12%),
espite  the  fact  that  physicians  were  allowed  to  make
hanges  to  medications  once  the  6-month  primary  endpoint
as  reached  (ACC  2012  meeting).
The  percentage  of  responders  (deﬁned  as  an  arbitrary
hreshold  of  greater  or  equal  to  10  mmHg  decrease  in  SBP)
as  85%  in  the  group  treated  by  renal  denervation  and  35%
n  the  medically  treated  group  (P  <  0.0001).  This  information
as  not  reported  for  the  35  patients  who  crossed  over  as  per
rotocol.
ABP  was  assessed  before  and  after  6-month  follow-up
n  only  20  patients  in  the  renal  denervation  group.  The
mbulatory  SBP/DBP  reduction  was  only  —11/—7  mmHg
P  =  0.006/0.014  vs  baseline).  The  reduction  was
3/—1  mmHg  in  the  control  arm  (P  =  not  signiﬁcant  vs
aseline).  No  ABP  data  are  available  for  the  35  patients
ho  crossed  over  as  per  protocol.
Renal  denervation  yielded  no  BP  beneﬁt  in  the  10%  of
atients  initially  randomized  to  renal  denervation.  This
nformation  was  not  reported  for  the  35  patients  who
rossed  over  as  per  protocol.
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Table  1  Effects  of  renal  denervation  on  blood  pressure  in  the  SYMPLICITY  HTN-1  and  HTN-2  trials.
Inclusion    at
1 month
  at
3 months
  at
6 months
  at
9 months
  at
12  months
  at  24  months
Pilot  study  (SYMPLICITY
HTN-1)
Ofﬁce  BP  (mmHg) 177/101
(n  =  45)
—14/—10
(n  =  41)
—21/—10
(n  =  39)
—22/—11
(n  =  26)
—24/-11
(n  =  20)
—27/—17
(n  =  9)
ABP  (n  =  12),  mean
24  hours  (mmHg)
—11 ±  7
(n  =  9)
Randomized  study
(SYMPLICITY  HTN-2)
Ofﬁce  BP  (mmHg)  178/97
(n  =  52)
—20/—6a
(n  =  49)
—33/—11a
(n  =  49)
—28/—10b
(n  =  47)
HBP  (mmHg) —22/—12a
(n  =  32)
ABP,  mean  24  hours
(mmHg)
—8/—6a
(n  =  20)
ABP: ambulatory blood pressure; BP: blood pressure; HBP: home blood pressure.
a Versus control.
b Versus baseline.
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wThe  reduction  in  BP  did  not  occur  immediately  after  the
rocedure;  the  maximum  effect  was  observed  after  about
—3  months  of  follow-up.
Antihypertensive  treatment  (medications  and  doses)  was
ot  reduced  in  the  majority  of  study  patients  (20%  in  the
enervation  group  and  6%  in  the  control  arm,  P  =  0.04),  and
omplete  treatment  discontinuation  was  not  achieved  in
ny  patient.  In  the  35  patients  who  crossed  over,  the  anti-
ypertensive  treatment  was  decreased  in  six  patients  and
ncreased  in  ﬁve  patients.
mpact of renal denervation on sympathetic
erve activity
he  decrease  in  overall  and  renal  sympathetic  nerve  activity
as  assessed  in  10  patients  in  the  SYMPLICITY  HTN-1  study:
here  was  a  decrease  in  muscle  sympathetic  nerve  activity
nd  a  47%  reduction  in  renal  noradrenaline  spillover,  30  days
fter  renal  denervation.
omplications of catheter-based renal
enervation
atients  experience  intense  visceral  and  diffuse  pain  during
he  2-minute  ablation  sequences.  It  is  thus  mandatory  to
rovide  the  patients  with  appropriate  analgesia,  which  may
e  administered  by  an  anaesthesiologist.
In  the  SYMPLICITY  HTN-2  trial,  atropine  was  required  in
/52  patients  who  experienced  bradycardia  during  the  pro-
edure.
Among  50  patients  in  the  SYMPLICITY  HTN-1  trial,  only
ne  case  of  renal  artery  dissection  and  one  case  of  femoral
seudoaneurysm  were  reported.
In the  SYMPLICITY  HTN-2  trial,  among  the  52  patients
ho  underwent  the  initial  procedure,  the  following
omplications  were  reported:  one  case  of  femoral
a
t
iseudoaneurysm;  one  case  of  arterial  hypotension  requir-
ng  a  reduction  in  the  number  of  hypertensive  medications;
ne  case  of  urinary  infection;  one  case  of  postprocedural
araesthesia;  and  one  case  of  lumbar  pain  resolving  after  1
onth.  Among  the  35  patients  who  crossed  over,  one  case
f  renal  artery  dissection  following  guide  catheter  insertion
uring  angiography  occurred;  the  lesion  was  stented  with-
ut  further  complication.  Additionally,  one  hospitalization
ue  to  hypotension  necessitating  intravenous  ﬂuids  occurred
ollowing  the  renal  denervation  procedure;  the  antihyper-
ensive  medications  were  decreased  and  the  patient  was
ischarged  without  further  incident.  Three  hypertensive
vents  requiring  hospitalization  occurred  in  two  patients.
Long-term  follow-up  (24  months)  of  the  extended  open-
abel  study  cohort  of  SYMPLICITY  HTN-1  [18], involving  153
atients,  showed  one  case  of  renal  artery  dissection  and
hree  cases  of  femoral  pseudoaneurysm.
Six-month  anatomical  follow-up  of  the  renal  arteries  of
3  patients  enrolled  in  the  SYMPLICITY  HTN-2  trial  and  81
atients  included  in  an  open-label  substudy  did  not  reveal
ny  vascular  lesions  of  the  renal  arteries.  One  case  of
orsening  renal  arterial  stenosis  requiring  angioplasty  was
eported  at  6-month  follow-up.
In  the  SYMPLICITY  HTN-2  trial,  the  GFR  of  49  patients
ith  a  baseline  value  greater  than  45  mL/min/1.73  m2
emained  stable  6  months  after  the  denervation  procedure.
he  absence  of  GFR  variation  was  conﬁrmed  at  12  months
ACC  2012  meeting).  No  long-term  data  beyond  this  time
eriod  are  available  to  date.
There  was  no  death  during  follow-up  in  the  SYMPLICITY
TN-2  trial.  Two  deaths  were  reported  in  the  study  cohort
ho  reached  24-month  follow-up  (one  myocardial  infarction
nd  one  sudden  death);  these  deaths  were  not  attributed  to
he  denervation  procedure.
Overall,  early  adverse  events  were  reported  in  approx-
mately  3—4%  of  patients  enrolled  in  these  studies.  The
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low  number  of  highly  selected  patients  included  in  these
studies,  who  were  under  very  close  medical  supervision,  pre-
cludes  any  elimination  of  a  potential  severe  adverse  event
risk  with  a  less  than  5%  frequency  at  short-,  mid-  and  long-
term  follow-up.  This  warrants  long-term  clinical  and  imaging
follow-up  in  patients  undergoing  renal  denervation.
Critical assessment of data issued from trials
assessing the beneﬁt/risk ratio of renal
denervation for the treatment of resistant
hypertension
The  limitations  characterizing  the  results  of  published  stud-
ies  are  as  follows:  the  number  of  patients  enrolled  in  these
studies  is  small  and  the  population  is  highly  selected  (202
patients  with  published  outcome  to  date);  the  shortness
of  the  follow-up  duration  precludes  risk  assessment  for
infrequent  or  long-term  adverse  events;  not  all  patients
included  in  these  studies  were  on  optimal  hypertensive
treatment—indeed,  5—10%  of  patients  were  not  taking  any
diuretics  and  less  than  20%  were  prescribed  a  mineralocor-
ticoid  receptor  antagonist;  the  majority  of  patients  did  not
have  ABP  or  HBM  measurements,  which  allow  detection  of
uncontrolled  hypertension  in  patients  prone  to  the  white-
coat  effect;  the  long-term  BP  outcome  beyond  36  months
is  unknown  (it  was  reported  for  a  very  limited  number  of
patients  at  24  months  [n  =  59]  and  at  36  months  [n  =  24]  for
the  extended  cohort  study  [ACC  2012  meeting]);  there  are
no  criteria  allowing  accurate  prediction  of  the  degree  of  BP
reduction  resulting  from  catheter-based  renal  denervation;
currently  in  daily  practice,  there  are  no  available  markers
of  the  impact  of  renal  denervation  on  the  renal  sympathetic
system  during  and  following  the  procedure;  and  analysis  of
the  effect  of  renal  denervation  on  sympathetic  system  acti-
vation  by  complex  experimental  technical  strategies  is  not
feasible  in  clinical  practice.
Therefore,  further  studies  are  warranted  in  order  to
address  unresolved  issues  with  respect  to  the  implemen-
tation  of  renal  denervation  for  treatment  of  resistant
hypertension,  which  include:  quantiﬁcation  of  BP  decreases
using  ABP  and/or  HBP  monitoring;  predictive  factors  of  the
efﬁcacy  of  catheter-based  renal  denervation  on  BP;  imme-
diate  procedural  efﬁcacy  endpoints  of  renal  denervation;
long-term  assessment  of  BP  efﬁcacy  and  anatomical  evolu-
tion  of  the  renal  arteries;  and  cost-effectiveness  assessment
of  catheter-based  renal  denervation  as  part  of  the  manage-
ment  strategy  for  resistant  hypertension.
Indications for catheter-based renal
denervation in the treatment of resistant
hypertension in 2012
According  to  the  2012  expert  consensus,  indications  for
catheter-based  renal  denervation  should  be  restricted  to
patients  with  resistant  arterial  hypertension  despite  the  use
of  four  or  more  antihypertensive  drugs  and  with:  treat-
ment  that  includes  at  least  a  diuretic  (thiazide  or  loop
diuretic  if  needed);  past  or  present  exposure  to  spirono-
lactone  (at  a  dose  ≥  25  mg/d);  ofﬁce  SBP  greater  than
160  mmHg  and/or  DBP  greater  than  100  mmHg,  conﬁrmed
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y  daytime  ABP  or  HBP,  with  SBP  greater  than  135  mmHg
nd  DBP  greater  than  85  mmHg;  an  estimated  GFR  greater
han  45  mL/min/1.73  m2; suitable  renal  arterial  anatomy  for
enal  denervation  (see  below);  the  presence  of  two  func-
ional  kidneys  greater  or  equal  to  90  mm;  a  preprocedural
xamination  of  the  renal  arteries  by  computed  tomography
ngiography,  magnetic  resonance  angiography  or  conven-
ional  angiography;  no  history  of  angioplasty/stenting  of  the
arget  renal  arteries;  a  peripheral  vascular  access  compati-
le  with  catheterization;  and  the  decision  to  carry  out  the
enervation  procedure  taken  by  a  multidisciplinary  ‘renal’
eam,  including  a  physician  specialized  in  the  management
f  patients  with  resistant  hypertension.
The  renal  denervation  technique  should  not  be  per-
ormed  in  hypertensive  patients  with  the  following
haracteristics:  renal  artery  stenosis  greater  than  30%;  renal
rtery  ﬁbromuscular  dysplasia;  age  less  than  18  years;  preg-
ant.
ecommended procedural technique for
erformance of catheter-based renal
enervation
he  procedural  technique  for  and  organization  of  endovas-
ular  renal  denervation  recommended  in  the  2012  expert
onsensus  guidelines  are  outlined  below.
echnical requirements
he  technical  facilities  should  include  an  angiogra-
hy/catheter  laboratory  providing:  appropriate  visualiza-
ion  of  the  two  nephrograms  by  bilateral  angiography;
igh-quality  X-ray  equipment  (the  use  of  an  operating  room
-arm  is  not  adapted  to  this  intervention);  and  optimal  pro-
ection  against  X-ray  exposure.
Images  (cine  views)  must  include  images  of  the  kidneys
left  and  right  renal  arteries)  before  and  after  renal  dener-
ation  conﬁrming  the  absence  of  dissection  or  renal  embolic
omplications.  The  angiographic  views  at  the  beginning  and
he  end  of  the  procedure,  as  well  as  the  position  of  the
atheter  at  all  ablation  sites,  should  be  recorded  and  stored
n  a  computerized  system.
The  angiography/catheter  laboratory  should  be  located
n  a  facility  where  analgesia/sedation  can  be  safely  admin-
stered  by  anaesthesiologists.
perator training
enal  denervation  is  a  complex  procedure  that  may  generate
ncreased  risks  of  renal  and  vascular  complications  as  well
s  procedural  failure  due  to  inappropriate  procedure.  Prior
raining  is  deemed  necessary  before  the  ﬁrst  procedures  can
e  safely  performed,  especially  during  the  learning  phase  for
peciﬁc  equipment  use.
Interventional  radiologists  and  cardiologists  should  have
revious  experience  of:  at  least  15  renal  artery  angioplasties
ith  or  without  stent  placement;  or  at  least  10  renal  artery
ngioplasties  and  50  peripheral  artery  angioplasties  over  the
receding  2  years;  or  regular  performance  of  renal  angio-
lasty  in  the  previous  5  years  and  regular  performance  of
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enal  artery  catheterization  for  all-indication  embolization
10  per  year  in  the  two  previous  years).
adiofrequency renal denervation procedure
n  compliance  with  the  principles  of  arterial  catheteriza-
ion,  this  procedure  requires  the  insertion  of  a  single-use
peciﬁc  catheter  for  renal  denervation.  The  denervation
atheter,  homologated  for  its  use  in  the  renal  arteries,  is
onnected  to  a  low  energy  radiofrequency  generator.  The
fferent  and  efferent  nervous  ﬁbres  that  run  along  the
dventitia  of  the  renal  arteries  are  disrupted  by  the  ther-
al  effect  produced  by  heat  dissipation  of  radiofrequency
nergy.
The  method  should  be  implemented  using  a  standardized
echnique,  with  correct  positioning  of  the  catheter  tip  con-
rmed  by  visual  check  under  ﬂuoroscopy  and  by  impedance
easurement.  Regarding  delivery  of  radiofrequency  energy,
he  requirements  are:  2-minute  radiofrequency  pulse  deliv-
ry  sequences  (the  energy  delivered  via  the  catheter  and
he  temperature  should  be  recorded  in  real  time);  deliv-
ry  of  radiofrequency  energy  repeated  four  to  six  times  in
ach  renal  artery;  circumferential  denervation  following  a
elicoidally  pattern  by  removal  of  the  catheter  using  60◦ to
0◦ rotation  of  each  5-mm  segment,  starting  from  the  dis-
al  ablation  area  close  to  the  bifurcation  of  the  main  renal
rtery  up  to  its  ostium;  and  cooling  of  the  tip  of  the  catheter
y  blood  ﬂow.
Renal  denervation  is  feasible  in  instances  where  the  fol-
owing  criteria  are  met:  renal  artery  diameter  greater  than
 mm  on  both  sides;  trunk  of  the  main  renal  artery  greater
r  equal  to  20  mm  in  length  in  order  to  allow  at  least  four
o  six  radiofrequency  ablation  sequences;  and  treatment  of
nly  one  artery  in  each  kidney.
The  following  measures  are  required  during  the  proce-
ure:  monitoring  of  vital  variables  (heart  rate  and  BP);
nticoagulation  with  adjusted-dose  heparin  according  to  the
otice  for  use;  preprocedural  injection  of  nitrates  in  each
enal  artery;  postprocedural  check  of  pacemaker  or  deﬁbril-
ator  programming  in  patients  with  such  devices  undergoing
enal  denervation;  and  administration  of  appropriate  anal-
esic  drugs  for  pain  management.
Vascular  complications  during  the  procedure  should  be
anaged  as  follows:  the  catheterization  laboratory  should
e  equipped  with  the  appropriate  devices,  allowing  urgent
mplantation  of  a  stent  in  the  renal  artery  in  cases  of  dis-
ection;  the  radiofrequency  procedure  should  be  completely
iscontinued  in  the  event  of  a  vascular  complication  occur-
ing  in  one  of  the  renal  arteries;  complications  should  be
eported  to  the  centre’s  equipment  safety  monitoring  com-
ittee.
ecommendations for monitoring and
ollow-up of patients undergoing
ndovascular denervation for treatment of
esistant hypertensionhort-term  monitoring  should  follow  the  rules  of  manage-
ent  of  patients  after  renal/peripheral  angioplasty.  Patient
onitoring  for  1  hour  postprocedure  in  the  recovery  unit  and
T
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 24-hour  hospital  stay  are  recommended.  Ofﬁce  BP  should
e  checked  at  1,  3,  6,  12,  24  and  36  months  postprocedure.
BP  and/or  HBP  monitoring  should  be  checked  at  least  at  6,
2,  24  and  36  months  after  the  renal  denervation  procedure.
Renal  artery  imaging  by  computed  tomography  scan
hould  be  performed  at  12  and  36  months  following  the  renal
enervation  procedure.  In  the  absence  of  an  acute  compli-
ation,  monitoring  of  plasma  creatinine  and  albuminuria  (in
atients  with  baseline  albuminuria)  should  be  done  at  6,
2,  24  and  36  months  following  the  renal  denervation  pro-
edure.
Antihypertensive  treatment  should  not  be  discontinued
mmediately  after  the  renal  denervation  procedure  because
he  expected  decrease  in  BP  is  delayed  and  reaches  its
eak  after  about  2—3  months,  according  to  the  ﬁndings  of
he  SYMPLICITY  trial.  Any  change  in  hypertensive  treatment
hould  be  prescribed  by  the  specialized  physician  speciﬁcally
anaging  the  hypertension.
The  expert  consensus  requires  the  inclusion  of  patients
xperiencing  this  procedure  in  an  observational  study  (reg-
stry).
onclusions
atheter-based  renal  artery  denervation  is  still  a  technique
n  its  very  early  development.  Despite  promising  prelim-
nary  results,  several  uncertainties  remain  regarding  its
eneﬁt/risk  ratio.  The  French  consensus  group  recommends
hat  renal  denervation  should  be  restricted  to  patients  with
ssential  resistant  hypertension  until  further  information  is
vailable.  These  recommendations  will  be  regularly  updated
ccording  to  technical  and  clinical  progress  in  the  ﬁeld  of
enal  denervation.  The  expert  consensus  requires  that  all
atients  undergoing  renal  denervation  should  be  included  in
 prospective  registry  conducted  by  the  French  Societies  of
rterial  Hypertension,  Cardiology  and  Radiology,  in  order  to
rovide  real-life  assessment  of  the  beneﬁt/risk  ratio  of  this
ew  technique.
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